EGFR and non-small cell lung carcinoma: Osimertinib, one of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), had an established efficacy and safety profile as first- and second-line therapy in NSCLC, it can penetrate BBB and showing better efficacy than gefitinib in BM patients.